Browsing Tag
hidradenitis suppurativa
10 posts
Insmed (NASDAQ: INSM) rebounds as retail eyes ATS 2026 readouts after Q1 reset
INSM bounced 11% after a 20% post-earnings reset. BRINSUPRI is launching faster than any respiratory drug in a decade. So why did the market sell the print?
Incyte (NASDAQ: INCY) moves closer to an hidradenitis suppurativa launch as 54-week povorcitinib data hold up
Incyte Corporation’s new 54-week povorcitinib data could reshape hidradenitis suppurativa treatment. Read what it means for INCY now.
How pediatric biologic approvals are transforming hidradenitis suppurativa treatment
Novartis AG expands Cosentyx approval to adolescents with hidradenitis suppurativa. Discover what this means for dermatology biologics and investors.
MoonLake Immunotherapeutics says FDA supports existing clinical data for sonelokimab, announces investor day amid strong market reaction
Find out how MoonLake Immunotherapeutics gained FDA support for its sonelokimab data and why investors are watching its 2026 regulatory path closely.
InflaRx prepares for key INF904 Phase 2a topline readout in chronic skin inflammation trials
Find out how InflaRx’s INF904 topline Phase 2a data could redefine treatment for hidradenitis suppurativa and chronic spontaneous urticaria.
Kymera Therapeutics advances Phase 2 trials of KT-474 in partnership with Sanofi
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a leader in the biopharmaceutical sector focusing on targeted protein degradation (TPD), has…
UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global…
FDA approves Novartis’ Cosentyx for hidradenitis suppurativa treatment
Novartis, a global leader in immuno-dermatology and rheumatology, announced the U.S. Food and Drug Administration’s approval of Cosentyx…
Acelyrin boosts immunology pipeline through acquisition of ValenzaBio
Acelyrin has acquired ValenzaBio, a privately held clinical-stage biopharmaceutical company, in an all-stock deal. With the acquisition of…
Janssen to acquire skin disease drug candidate bermekimab from XBiotech
Janssen Biotech acquisition of bermekimab: Janssen Biotech, a Janssen Pharmaceutical Company of Johnson & Johnson, has agreed to…